Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 1
2013 1
2014 2
2015 5
2016 6
2017 1
2018 1
2020 3
2021 2
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Clinicopathologic features, tumor immune microenvironment and genomic landscape of EBV-related and EBV-unrelated poorly differentiated nonkeratinizing squamous cell carcinoma of the thymus.
Zhang YJ, Xiong SP, Yang YZ, Fu S, Wang TM, Suster DI, Jiang GY, Zhang XF, Xiang J, Wu YX, Zhang WL, Cao Y, Huang YH, Yun JP, Liu QW, Sun Q, Chen Y, Yang X, Li Y, Wang EH, Liu JL, Zhang JB. Zhang YJ, et al. Among authors: liu qw. Lung Cancer. 2023 May;179:107178. doi: 10.1016/j.lungcan.2023.107178. Epub 2023 Mar 22. Lung Cancer. 2023. PMID: 37004385
Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients.
Wang D, Qiu B, Liu Q, Xia L, Liu S, Zheng C, Liu H, Mo Y, Zhang X, Hu Y, Zheng S, Zhou Y, Fu J, Chen N, Liu F, Zhou R, Guo J, Fan W, Liu H. Wang D, et al. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3400-3413. doi: 10.1007/s00259-023-06298-x. Epub 2023 Jun 13. Eur J Nucl Med Mol Imaging. 2023. PMID: 37310427
Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.
Ma YX, Liu FR, Zhang Y, Chen Q, Chen ZQ, Liu QW, Huang Y, Yang YP, Fang WF, Xi N, Kang N, Zhuang YL, Zhang Q, Jiang YZ, Zhang L, Zhao HY. Ma YX, et al. Among authors: liu qw. Front Immunol. 2022 Oct 20;13:1024755. doi: 10.3389/fimmu.2022.1024755. eCollection 2022. Front Immunol. 2022. PMID: 36341335 Free PMC article. Clinical Trial.
27 results